Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

Oliver Surriga\textsuperscript{1,4}, Vinagolu K. Rajasekhar\textsuperscript{1,4}, Grazia Ambrosini\textsuperscript{1}, Yildrim Dogan\textsuperscript{2}, Ruimin Huang\textsuperscript{3} and Gary K. Schwartz\textsuperscript{1}

\textsuperscript{1}Jennifer Goodman Linn Laboratory of New Drug Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
\textsuperscript{2}Department of Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, New York
\textsuperscript{3}Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
\textsuperscript{4}Co-first Authors

Running Title: c-Met inhibition in metastatic uveal melanoma model

Key Words: Crizotinib, c-Met, metastasis, uveal, melanoma

To whom correspondence should be addressed:
Gary K. Schwartz, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, Ph 212 639 8324, Fax 212 717 3561, Email: schwartg@mskcc.org

Research grant support:
O. Surriga, V. Rajasekhar, G. Ambrosini and G.K. Schwartz received grant support from Cycle for Survival (Philanthropy)

Disclosure of Potential Conflicts of Interest:
There are no potential conflicts of interest.
ABSTRACT

Uveal melanoma is the most common primary intraocular malignant tumor in adults and half of the primary tumors will develop fatal metastatic disease to the liver and the lung. Crizotinib, an inhibitor of c-Met, anaplastic lymphoma kinase (ALK) and ROS1, inhibited the phosphorylation of the c-Met receptor but not of ALK or ROS1 in uveal melanoma cells and tumor tissue. Consequently, migration of uveal melanoma cells was suppressed *in vitro* at a concentration associated with the specific inhibition of c-Met phosphorylation. This effect on cell migration could be recapitulated with siRNA specific to c-Met but not to ALK or ROS1. Therefore, we developed a uveal melanoma metastatic mouse model with EGFP-luciferase-labeled uveal melanoma cells transplanted by retro-orbital injections to test the effect of crizotinib on metastasis. In this model, there was development of melanoma within the eye and also metastases to the liver and lung at 7 weeks after the initial transplantation. When mice were treated with crizotinib starting 1 week after the transplantation, we observed a significant reduction in the development of metastases as compared to untreated control sets. These results indicate that the inhibition of c-Met activity alone may be sufficient to strongly inhibit metastasis of uveal melanoma from forming, suggesting crizotinib as a potential adjuvant therapy for patients with primary uveal melanoma who are at high risk for the development of metastatic disease.
INTRODUCTION

Uveal melanoma is the most common primary intraocular malignant tumor in adults. Tumor epicenters are usually found in the choroid but may also arise from the iris and ciliary body. About 45% of uveal melanoma cases were recorded in adults over 60 years old and 53% were in adults aged between 21 and 60 years old (1). The 5-year survival rate of uveal melanoma patients from 1973-2008 is 81.6% (2). However, the prognosis is worse for patients that develop metastatic uveal melanoma with an overall 1- and 2-year survival rates of 13% and 8%, respectively (3, 4). About half of patients with uveal melanoma will develop metastasis, which primarily occurs in the liver (5, 6). In fact, nearly all uveal melanoma patients that die due to metastatic disease have liver metastasis (7). Uveal melanomas are characterized by mutations in the G-protein genes, \textit{GNAQ} and \textit{GNA11}. Although the loss of chromosome 3 (5, 8) and mutations in the \textit{BAP1} gene are additionally implicated in uveal melanoma metastasis (9, 10), there has been a considerable interest on the possible role of c-Met which is highly expressed in metastatic uveal melanoma tumors (5, 11).

The receptor tyrosine kinase, c-Met, is a 140-kDa transmembrane protein consisting of a disulfide-linked heterodimer with an extracellular α-subunit and a transmembrane β-subunit. When c-Met is bound to its ligand, hepatocyte growth factor (HGF), the autophosphorylation of tyrosine residues are initiated at Tyr1230/1234/1235 in the catalytic domain propagating a signaling cascade through a number of adaptor and effector proteins. This signaling results in the activation of the Ras-ERK, STAT and PI3K-AKT pathways which are implicated in oncogenic cell proliferation, survival and motility (12-14). However, a study has shown that the activation of the previously mentioned pathways through c-Met signaling may not be enough to
induce mitogenesis in the cells (15). Other receptor tyrosine kinases, namely epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and insulin-like growth factor 1 receptor (IGF1R) may work in conjunction with or propagate the activation of c-Met to initiate mitogenic pathways (6, 16, 17). Previous studies have shown that HGF influences migratory ability in vitro (18) and its self-expression may contribute to metastasis in vivo. Activated c-Met, a result of indirect gene activation rather than mutation, has also been found in uveal melanoma cell lines (19). Furthermore, previous studies have implicated the increased expression of c-Met in primary uveal melanoma tumors with the higher risk of liver metastasis (6, 11).

Crizotinib is a small molecule inhibitor that is selective for c-Met as well as anaplastic lymphoma kinase (ALK) and (ROS1). It has been shown to inhibit cell proliferation, migration and invasion of several tumor cell lines in vitro and it has also displayed significant antitumor activity in xenograft mouse models (20-22). It is approved for the treatment of ALK-expressing advanced and metastatic non-small cell lung cancer. Since the survival rate of uveal melanoma patients decreases as metastatic disease progresses and that previous studies suggest the significant role of c-Met in uveal melanoma metastasis, there may also be a potential for using crizotinib to prevent the development of metastatic uveal melanoma. This study, therefore, investigates the effects of crizotinib in uveal melanoma cell lines and in a metastatic uveal melanoma model.
MATERIALS AND METHODS

Cell culture and reagents

C918 and Mel290 were received from Robert Folberg in 2009 (University of Illinois, Chicago, IL). Mel285, Omm1.3 and Omm1 were kindly provided by Boris Bastian in 2010 (Memorial Sloan-Kettering Cancer Center, New York, NY). 92.1 was obtained from William Harbour in 2009 (Washington University, St. Louis, MO). C918 was derived from a patient tumor by Daniels et al (23). Mel290 and Mel285 were established from primary tumors by Bruce Ksander (Schepens Eye Research Institute, Boston, MA) (24). 92.1 was established from a primary tumor by Marline Jager (Leiden University Medical Center, Leiden, The Netherlands) (25). Omm1.3 was established from liver metastases also by Bruce Ksander (26). Omm1 was established from a patient’s subcutis metastatic lesion by G.P.M. Luyten (Rotterdam University Hospital, Rotterdam, The Netherlands) (27). Uveal melanoma cell lines have been sequenced for the presence of activating mutations in codons 209 (exon 5) and 183 (exon 4) of \textit{GNAQ} and \textit{GNA11}. 92.1 and Omm1.3 had \textit{GNAQ} mutation while Omm1 had \textit{GNA11} mutation. A karyotype test was also performed for each cell line in 2012. Cells were cultured in RPMI medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin and maintained at 37°C in 5% CO2. Crizotinib, graciously supplied by Pfizer (La Jolla, CA), was dissolved in dimethyl sulfoxide (DMSO) for \textit{in vitro} experiments and formulated in water for animal studies.

ELISA

For each uveal melanoma cell line, 2 million cells were used to seed 60 mm plates in 3 mL volume of serum-free RPMI media in duplicates. Cells were allowed to grow for 24 hours and
the media were collected and centrifuged. The supernatants were used in the R&D Systems Quantikine® ELISA Human HGF Immunoassay according to the manufacturer’s instructions. Serum-free media from unseeded plates were used to subtract the background. The presence of HGF in the media is expressed as pg/mL concentrations and the minimum detectable dose of the assay is less than 40 pg/mL.

**Immunoblotting**

Cells and tissues were lysed with radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor cocktail tablets (Roche Diagnostics) and 1 mmol/L Na₃VO₄. Equal amounts of protein were loaded on 4% to 12% PAGE gels (Invitrogen, Carlsbad, CA). Polyvinylidene difluoride (PVDF) membranes were blocked with 5% nonfat dried milk and probed with p-Met (Y1234-1235), Met, p-ALK (Y1096), ALK, p-ROS1 (Y2274), ROS1, p-STAT3 (Y705), STAT3, p-AKT (S473), AKT, p-ERK 1/2 (T202/Y204), ERK 1/2, cleaved PARP, α-tubulin (Cell Signaling Technology, Danvers, MA) and human HGF (Santa Cruz Biotechnology, Santa Cruz, CA).

**Gene silencing**

Cells were plated on 60-mm plates, and transfected with control, c-Met, ALK or ROS1 siRNA using Lipofectamine® RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. The transfections were performed twice, each time in overnight incubations with a recovery phase of 6 hours in between transfections. The siRNA sequences for control, c-Met, ALK and ROS1 were purchased from Cell Signaling Technology, Inc. (Danvers, MA).

**Cell viability assays**
Cells were plated in 96-well plates and treated in triplicates with the indicated concentrations of crizotinib or DMSO. Viability was assessed after 72 hours of treatment using the Cell Counting Kit 8 (CCK8) from Dojindo Molecular Technologies (Rockville, MD) according to the manufacturer’s instructions. Survival is expressed as a percentage of untreated cells. For the c-Met siRNA viability assay, cells were harvested after transfection and grown in triplicates in 96-well plates for 72 hours. Viability was assessed as previously described.

**Migration assays**

Cells were seeded and treated with DMSO, 25 nmol/L or 250 nmol/L crizotinib for 24 hours in media with 0.1% serum on BioCoat™ Matrigel™ Invasion Chambers (BD Biosciences, San Jose, CA) according to manufacturer’s instructions. RPMI medium with 10% serum and 50 ng/ml HGF was used as chemoattractant. Non-invading cells were then removed from the matrigel and cells on the other side of the matrix were fixed with 100% methanol and stained with 1% Toluidine Blue. Images of stained cells were taken through a microscope. For the c-Met, ALK and ROS1 siRNA migration assay, cells were harvested after double transfection and seeded in triplicates on invasion chambers for 24 hours as mentioned above. RPMI medium with 10% serum and no HGF was used as chemoattractant. Images of stained cells were obtained from three random sections of each matrigel to account for cell distribution. Invading cells were then quantified by adding cells from the three sections and calculating the mean of each triplicate. Migration is expressed as the number of cells migrated.

**Xenograft studies**

8-week-old NU/NU SCID male mice bearing subcutaneously injected Omm1.3 or 92.1 tumors (9 mice/cohort) of ~100 mm³ diameter were treated orally (p.o.) with vehicle control (water) or crizotinib (50, 75 and 100 mg/kg/d) 5 days/week for 3 weeks. Tumors were measured every 2 to
3 days with calipers and tumor volumes were calculated and expressed in cubic millimeter and calculated using the formula $p/6 \times (\text{large diameter}) \times (\text{small diameter})$. Toxicity was monitored by weight loss. Two animals from each cohort were sacrificed 1-3 hours after the fifth treatment and tumors were collected. Tumor tissues were carefully dissected from the surrounding stroma and were immediately flash frozen in liquid nitrogen. Frozen tumors were ground in tubes with resin and RIPA buffer following procedures set for Sample Grinding Kit (GE Healthcare). The Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee and Research Animal Resource Center specifically approved this study. The study also complied with the Principles of Laboratory Animal Care (NIH Publication No. 85–23, released 1985). All efforts were made to minimize suffering.

**Construct and preparation of recombinant lentivirus**

An FUGW-based lentiviral vector encoding EGFP/luciferase fusion gene (FUGLW) under the ubiquitin promoter was used to infect the uveal melanoma tumor cells. The viral supernatant was prepared by cotransfecting 293T cells with the FUGLW, pCMV-d8.91and pMD2.G vectors. Viral transduction was performed as previously described by Dogan et al (28).

**Metastatic model**

Omm1.3 cells were stably infected with a lentiviral construct to constitutively express the GFP-Luciferase fusion protein. EGFP-positive cells were then enriched by fluorescence-activated cell sorting (FACS). 8-week-old NU/NU SCID male mice were anesthetized with 3% isoflurane and 10 million cells were administered in 50 μL PBS through retro-orbital injection. One week later, animals were treated orally (p.o.) with vehicle control or 50 mg/kg crizotinib daily 5 days/week for 9 weeks. Luciferase activity was monitored weekly to detect metastasis progression. At the endpoint, livers and lungs were harvested for immunoblotting and immunohistochemistry.
Experiments were carried out under institutional guidelines addressing the proper and humane use of animals. The Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee and Research Animal Resource Center specifically approved this study. The study also complied with the Principles of Laboratory Animal Care (NIH Publication No. 85–23, released 1985). All efforts were made to minimize suffering.

**Bioluminescence imaging in vivo**

The imaging procedure was performed under 2.5% isoflurane anesthesia. The animals were injected retro-orbitally with potassium D-luciferin (30 mg/kg, Caliper, Waltham, MA) and imaged immediately after injection using an IVIS 200 imaging system (Caliper). Living Image software (version 4.0) was used to acquire and quantify the absolute bioluminescence intensity (photons/sec). Regions of interest (ROIs) for both metastatic tumors and background were selected from equivalent-sized areas. The background intensity was subtracted from the signal intensities.

**Histopathology**

For immunohistochemical analysis, representative sections of tumors were de-paraffinized, rehydrated in graded alcohols, and subjected to antigen retrieval by microwave oven treatment using standard procedures. H&E staining was carried out using Gill's hematoxylin (Poly Scientific R&D Corp., Bay Shore, NY, USA) for 10 min as per the manufacturer's protocol, followed by counterstaining with eosin (Poly Scientific R&D Corp., Bay Shore, NY) for 4 min. The immunohistochemistry was performed at the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center using MIRAX Slide Scanning System (PerkinElmer, Waltham, MA).
**Statistical analysis**

All *in vitro* experiments were carried out at least 2–3 times. For *in vitro* and *in vivo* studies, $P$ values were calculated using Student’s t-Test. We selected $P$ values $\leq 0.05$ as being statistically significant. Standard error was calculated as the standard deviation divided by the square root of the number of samples.
RESULTS

c-Met expression and HGF secretion in uveal melanoma cells

We evaluated the expression of the c-Met receptor and its basal phosphorylation status in uveal melanoma cells grown in serum-free media for 24 hours (Fig. 1A). All uveal melanoma cell lines tested express the c-Met receptor, represented by a 170 kDa precursor and a 145 kDa mature receptor. Examination of the sum of the two bands indicates that the cell lines with G-protein mutations namely, 92.1, Omm1.3 and Omm1, expressed relatively more c-Met than the wild-type cell lines namely, C918, Mel290 and Mel285. Phospho-Met was also relatively higher in G-protein mutant cell lines than wild-type cell lines, particularly in Omm1.3 cells which had the most receptor phosphorylation. Since the phosphorylation of c-Met is stimulated by the ligand, HGF, we investigated the ability of uveal melanoma cells to secrete HGF in serum-free media using ELISA (Fig. 1B). After a 24-hour incubation period, cells released HGF ranging from 70 pg/mL to 190 pg/mL. The cell lines with G-protein mutations, 92.1, Omm1.3 and Omm1, secreted more HGF than the wild-type cell lines, C918, Mel290 and Mel285, suggesting that uveal melanoma cell lines with G-protein mutation may be activating the c-Met phosphorylation through an autocrine signaling mechanism.

Suppression of c-Met by siRNA knockdown inhibits migration of uveal melanoma cells

Since dysregulated c-Met induces tumor growth, angiogenesis and metastasis, we tested the effects of c-Met downregulation on cell proliferation and migration of these uveal melanoma cell lines. Western blot analysis confirmed decreased levels of c-Met in all the cell lines transfected with c-Met siRNA (Fig. 2A and Fig. 2B). In cell viability assays, cell growth was not affected by c-Met knockdown (Fig. 2C). On the other hand, c-Met siRNA significantly inhibited cell
migration \( (p < 0.05) \) (Fig. 2D and Supplementary Fig. 1) and this effect was independent of G-protein status. In view of the fact that crizotinib is also an inhibitor of ALK and ROS1 kinases, we employed the siRNA knockdown strategy in suppressing ALK and ROS1 (Fig. 2B) to investigate whether these kinases have any effect in uveal melanoma migration. ALK and ROS1 knockdown did not significantly inhibit the migration of uveal melanoma cells (Fig. 2D and Supplementary Fig. 1). There was a slight decrease in migration of Omm1 cells transfected with ALK and ROS1 siRNA, but it was not statistically significant \( (p > 0.05) \). Collectively, these results indicate that cell migration of uveal melanoma cells is dependent on activated c-Met but not ALK or ROS1 and selectively suppressing c-Met decreases cell migration.

**Crizotinib inhibits migration of uveal melanoma cell lines**

We next elected to determine whether crizotinib would have a similar effect on cell migration. For these studies, we wanted to select the minimal concentration necessary to selectively inhibit p-Met but would have no effect on cell growth. The effects of crizotinib on the cell growth of uveal melanoma cell lines, wild-type \( (WT) \) or mutant for \( GNAQ \) and \( GNA11 \), were evaluated using a range of concentrations from 10 nmol/L to 3000 nmol/L (Fig. 3A). After 72 hours of treatment, all uveal melanoma cell lines showed a dose-dependent decrease in cell viability in response to crizotinib treatment. However, this effect only occurred at doses \( \geq 1,000 \) nmol/L. We found that c-Met phosphorylation was inhibited by crizotinib starting at 25 nmol/L, while neither ALK nor ROS1 was inhibited at any of the concentrations tested with 24 hours of drug exposure (Fig 3B). In view of this, we elected to test crizotinib at 25 nmol/L in a 24-hour migration assay. As shown in figure 3C, when uveal melanoma cells were treated with 25 nmol/L of crizotinib, a mutation-dependent effect was observed such that only the migration of G-protein mutant cells lines and not G-protein wild type cell lines (C918 and Mel290) was
decreased. However, when treated with 250 nmol/L crizotinib for 24 hours (conditions under which cell proliferation was still not affected), the migration of all cell lines was inhibited irrespective of mutational status (Supplementary Fig. 2), suggesting that G-protein mutant cells with higher basal activity of c-Met (Figures 1A and 3B) are sensitive to lower concentrations of the drug.

**Crizotinib has marginal effects on tumor growth inhibition in uveal melanoma xenografts**

To examine the effects of c-Met inhibition *in vivo*, we developed a subcutaneous xenograft model by particularly exploiting two uveal melanoma *GNAQ*-mutant cell lines, one (92.1 cell line, Fig. 4A) derived from a primary tumor and the other (Omm1.3 cell line, Fig. 4B) derived from a metastatic tumor. The mice were treated with vehicle control or 50 mg/kg crizotinib orally 5 times a week for 3 weeks, the maximally tolerated dose in the mice. Comparison of average tumor volume between the control and treated groups show that there were very minimal effects on crizotinib-mediated inhibition of tumor growth from both the primary and the metastatic cell lines (*p* > 0.05). Therefore, we examined whether the drug inhibited its target kinases and the downstream signaling pathways (Fig. 4C). Although, the administration of this drug dose resulted in a complete inhibition of phosphorylation of c-Met, there was no inhibition in phosphorylation of the other target kinases, p-ALK and p-ROS1. Importantly, the common downstream signaling components also appeared to be generally unaffected as determined by unchanged levels of p-AKT, p-ERK and p-STAT3. There was a slight decrease in p-ERK1/2 in the Omm1.3 cells, though this could be due to a decrease in total ERK1/2 protein expression.

The detection of human HGF expression in the tumor xenografts supports the hypothesis that HGF may activate c-Met through an autocrine activating loop in these cells. Apoptosis signaling at least via PARP cleavage was not observed in this study. There was no significant weight loss
with this dose of crizotinib in either animal study (Supplementary Fig. 3A and 3B) and also attempts to increase the drug dose to 75 and 100 mg/kg respectively also showed no appreciable reduction in tumor volume though this was associated with some modest weight loss (Supplementary Fig. 4A and 4B).

**Crizotinib prevents macrometastasis of uveal melanoma cells from developing in vivo**

As there was only a minimal inhibition of tumor growth in vivo and that crizotinib inhibits migration in vitro, we next elected to determine whether crizotinib would prevent uveal melanoma metastasis in vivo. Therefore, we first developed a novel mouse model that represents a retro-orbital delivery of the uveal melanoma cells into circulation. The Omm1.3 cells were labeled with the EGFP-Luciferase fusion protein. Thus, the labeled cells allowed us to verify the instant delivery of the transplanted cells and to monitor the mice for the subsequent development of metastatic disease by positron emission tomography (PET) imaging. To investigate the role of activated c-Met in these uveal melanoma cells, the mice were treated with 50 mg/kg crizotinib daily 5 days/week for 9 weeks starting from 7 days after the transplantation and were monitored weekly for the development of metastatic disease. Metastases were first observed 7 weeks later at which time most of the vehicle control mice showed strong luciferase activity in the eye, as well as at distant sites predominantly the liver and the lungs, whereas in crizotinib-treated mice, bioluminescence was predominantly seen at the site of primary transplantation (i.e. the eye) (Fig. 5A). Luciferase activity was dramatically inhibited in the treated mice (p = 0.03), as determined by quantification of bioluminescence signal intensity (Fig. 5B). Necropsy images from representative vehicle-treated control animals show macroscopic tumors, substantiated by the bioluminescence in the livers, while there were no distinguishable tumors in the livers of crizotinib-treated mice (Fig. 5C). There was bioluminescence signal in the lungs of untreated
animals, yet again there were no detectable bioluminescence signal in the lungs of treated animals. It is important to note that the uveal melanoma tumor growth in the eye of the mice was not inhibited by crizotinib. An H&E staining of liver sections from both cohorts verified the presence of metastatic tumor in the liver of untreated mice but not in the liver of crizotinib-treated mice (Fig. 5D). Two weeks after the end of drug treatment (i.e., on week 11), bioluminescence imaging showed continued tumor growth in the eye (the primary site), and in multiple distant sites, when compared to the mice treated with crizotinib (Supplementary Fig. 5A). In crizotinib-treated mice, metastases largely remained inhibited. Necropsy of the vehicle treated mice revealed bioluminescence in the liver, lung, kidney and spleen (Supplementary Fig. 5B). In addition, at week 11 the mice that previously responded to crizotinib now revealed small metastases in the liver.
DISCUSSION

The development of macroscopically detectable metastasis occurs in 50% of patients with uveal melanoma within 15 years of initial diagnosis, even after treatment and removal of the primary tumor (29). In our study, crizotinib inhibited c-Met phosphorylation and prevented uveal melanoma from forming macroscopic metastatic disease in a mouse model. We also observed a lack of anti-proliferative effects by crizotinib at doses that selectively inhibit only c-Met. Interestingly, there was inhibition of cell growth in vitro at high concentrations of crizotinib but this can be attributed to potential off-target effects. There was also an observed increased expression of c-Met and ALK in Mel285 and Omm1 cells in vitro as well as in Omm1.3 tissues after treatment with crizotinib. This may be a potential survival mechanism but more studies are needed to evaluate the significance of this observation. In our xenograft model, there was only a minimal effect on tumor growth which correlates with our in vitro study. Nevertheless, the xenograft studies do confirm inhibition of the target at the dose of drug administered. This is in contrast to past xenograft studies that have shown the potent antitumor activity of crizotinib in other tumor types (20-22). Other studies have found that the inhibition of c-Met alone may not be enough to prevent tumor growth in vivo and that other receptor tyrosine kinases such as EGFR and IGF1R are critical for uveal melanoma cell survival (30, 31). In fact, inhibition of either phospho-Met or phospho-EGFR resulted in activation of alternative pathways and blockade of both receptors resulted in maximal inhibition of the downstream kinases p-AKT and p-ERK 1/2 (16, 30). Another study also demonstrated that combining inhibitors of c-Met and VEGFR slowed down tumor growth (17). Thus, c-Met inhibition with crizotinib alone appears insufficient in preventing uveal melanoma tumor growth in vivo. This ultimately may require the development of combination therapies with inhibitors of IGFR1, VEGFR or EGFR.
In our *in vitro* studies, we found that a low nanomolar dose of crizotinib inhibited the migration of G-protein mutant cell lines but not wild-type cell lines. This may be explained by the higher basal levels of activated c-Met and secreted HGF which possibly induces an autocrine response that activates the c-Met receptor, rendering the GNAQ and GNA11 mutant cells more sensitive to the drug than wild-type cells. However, when a higher dose of crizotinib is used, there is significant inhibition of cell migration in all uveal melanoma cells, an effect that is independent of G-protein mutational status. This effect can be recapitulated with siRNA specific to c-Met which is not observed with siRNA for ALK or ROS1, the other targets of crizotinib. Previous studies have suggested the important role of c-Met overexpression in uveal melanoma metastasis and the regulation of its ligand, HGF, in determining tumor dissemination (32). Furthermore, c-Met-induced PI3K/AKT signaling has been linked to enhanced cell migration of uveal melanomas (33). Since we confirmed that c-Met plays a significant role in uveal melanoma cell migration, and that HGF is in fact expressed and secreted by these cells, a metastatic model was developed to demonstrate the inhibition of metastasis by crizotinib.

Other studies have shown hepatic, bone and visceral micrometastasis develop in a uveal melanoma xenograft model (34), as well as bone and visceral macrometastasis in an intracardiac metastatic mouse model (35). Another study has also demonstrated inhibition of micrometastasis using a VEGFR inhibitor after enucleation of the mouse eyes (36). In our study, we show that liver and lung metastases develop six to seven weeks after retro-orbital injection of EGFP-luciferase-infected uveal melanoma cells. We then demonstrated that crizotinib, at concentrations that inhibit p-Met *in vivo*, inhibited metastases from forming in the liver and lungs of the treated mice as compared to the control mice. We also observed that two weeks after stopping treatment with crizotinib, the mice previously treated with the drug showed traces
of metastasis in the liver, but this was still significantly less than the control mice. The subsequent progression of metastasis after termination of treatment further illustrates the dependence of metastatic disease on c-Met signaling. It also illustrates that crizotinib is unable to kill the microscopic metastases that develop rapidly in both the liver and lungs after retro-orbital injection, but rather it seems to either prevent the cells from migrating or spreading to dominant visceral sites, especially the liver. This inability to eradicate small volume disease ties in with the lack of single agent efficacy observed in our in vitro and in vivo studies. The detection of circulating malignant cells capable of developing hepatic micrometastasis has also been reported at the time of the initial diagnosis of patients with primary uveal melanoma (37). These cells may become dormant and later re-enter malignancy (38). It is conceivable that crizotinib is able to control these cells as long as the drug is maintained and then this inhibitory effect is lost once the drug is withdrawn allowing metastatic lesions to develop.

Consistent with our in vitro and xenograft studies, we saw no inhibition of growth in the development of the eye lesions, even after the initiation of crizotinib therapy in the treated animals. Though this could be due to a lack of drug penetration into the orbit of the mouse, this is most likely consistent with our observation that inhibition of c-Met activity by crizotinib in uveal melanoma cells is in itself not sufficient to decrease tumor growth. Clinically, though, this is not a critical issue. Patients with primary uveal melanoma either have enucleation of the eye to remove the primary tumor or have plaque radiation to eradicate primary cancer cells at presentation. Despite this approach, 50% of patients eventually develop metastatic disease and reoccurrence in the eye is exceptionally low (5, 6). The survival rate in uveal melanoma patients decreases dramatically with the onset of metastasis (3, 4). Therefore, the critical issue remains how to prevent development of metastatic disease after the treatment of the primary tumor.
These results suggest that it will be important to introduce preventive therapy as early as possible after initial presentation of this disease and that this therapy may need to be continued for the lifetime of the patient. There is now the potential to develop crizotinib as the first adjuvant therapy to prevent macro-metastatic disease from developing in uveal melanoma patients. Furthermore, with the metastatic uveal melanoma model we developed, more drugs can be screened to identify effective inhibitors against c-Met-dependent metastasis.
REFERENCES


FIGURE LEGENDS

**Figure 1:** Expression of c-Met in uveal melanoma cells and HGF secretion. A, cells were grown in serum-free media for 24 hours and lysed for immunoblot analysis. c-Met expression and phosphorylation is generally higher in cell lines with G-protein mutations. B, media from the plates were tested for the presence of HGF by ELISA. All cell lines secreted HGF but the average HGF secretion of G-protein-mutant cell lines was higher than the wild-type cell lines.

**Figure 2:** Effects of c-Met siRNA knockdown on cell proliferation and migration. A, uveal melanoma cells were transfected with control or c-Met siRNA. c-Met knockdown was verified by western blot analysis of the lysates. B, cells were transfected with control, c-Met, ALK or ROS1 siRNA. Western blot analysis of the lysates verified that all target genes were knocked down by their respective siRNA. C, transfected cells were plated in triplicates in 96-well plates and cell viability was measured after 72 hours as the percentage of control siRNA transfected cells. Knockdown of c-Met by siRNA does not affect the growth of uveal melanoma cell lines. D, transfected cells were seeded on matrigel chambers in triplicates and allowed to migrate for 24 hours into RPMI media containing 10% serum. Migrated cells were then quantitated. Only c-Met siRNA knockdown inhibits cell migration (*p = 0.003, †p = 0.002, ‡p = 0.004, §p = 0.039). There was a decrease in migration of Omm1 cells transfected with ALK and ROS1 siRNA but it was not significant (*p > 0.05).

**Figure 3:** Effects of crizotinib on cell growth and cell migration. A, uveal melanoma cells were plated and treated in triplicates with increasing doses of crizotinib for 72 hours in 96-well plates then cell viability was measured as the percentage of untreated controls. Crizotinib inhibited cell proliferation in a dose-dependent manner regardless of genotype only at higher concentrations.
The IC\textsubscript{50} range is from 750 nmo/L to 2000 nmol/L. B, cells were grown to 60% confluency in 60-mm plates then treated with increasing doses of crizotinib for 24 hours. Cells were then harvested and lysed for immunoblot analysis. c-Met was inhibited by crizotinib starting at 25 nmol/L but not p-ALK and p-ROS1. C, uveal melanoma cells were seeded on a matrigel chamber with 0.1% fetal bovine serum in RPMI and either DMSO or 25 nmol/L crizotinib. Cells were then allowed to migrate for 24 hours into media containing 10% FBS and 50 ng/mL HGF. The migration of GNAQ-mutant uveal melanoma cells was significantly inhibited when treated with 25 nmol/L crizotinib but not the migration of wild-type cell lines.

**Figure 4:** Tumor growth effects of inhibiting c-Met using crizotinib in uveal melanoma xenograft models. 8-week-old NU/NU SCID male mice bearing subcutaneously injected 92.1 tumors (A) or Omm1.3 tumors (B) of \( \sim 100 \) mm\textsuperscript{3} diameter were treated orally (p.o.) with vehicle or 50 mg/kg/d crizotinib 5 days/week for 3-4 weeks (9 mice/cohort). There was no significant tumor growth inhibition by crizotinib. The \( p \)-values were \( ^* p = 0.47, ^# p = 0.07 \). C, 92.1 and Omm1.3 tumors were collected from 2 mice per group. Protein lysates taken from frozen tumors were then immunoblotted to determine effects on c-Met signaling. Crizotinib completely inhibited p-Met \textit{in vivo} with no inhibition of other drug targets and downstream kinases in both models.

**Figure 5:** Inhibition of metastasis by crizotinib in a metastatic uveal melanoma model. Omm1.3 cells were stably infected with EGFP-luciferase and grown in large scale. The mice were then retro-orbitally injected with 10 million Omm1.3-EGFP-luciferase cells. One week after injection, the mice were treated with the vehicle or 50 mg/kg/d crizotinib 5 days a week for 9 weeks (10 control mice, 12 treated mice). The mice were imaged for luciferase activity every week. A, bioluminescence imaging at 7 weeks after injection of cells compared progression of
metastasis in control and crizotinib-treated mice. The control mice have metastasis in the abdominal region while crizotinib inhibited metastasis in the treated mice. B, bioluminescence intensity (BLI) was then quantified for each mouse and the mean calculated for each cohort. Luciferase activity in metastatic sites was significantly decreased in crizotinib-treated mice compared to the vehicle control ($p = 0.03$). C, necropsy images shows macrometastases in the liver and lungs of the control mouse while none were seen in the crizotinib-treated mouse. Bioluminescence imaging of the liver and lungs further illustrates inhibition of metastasis by crizotinib. D, H&E staining of liver tissue sections verify the presence of tumor in the control mouse liver but not in crizotinib-treated mouse liver.
Figure 1

A

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>p-Met</th>
<th>Total Met</th>
<th>p-ALK</th>
<th>Total ALK</th>
<th>Total ROS1</th>
<th>Tubulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>C918</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mel290</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mel285</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>92.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omm1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omm1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>pg/ml HGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>C918</td>
<td></td>
</tr>
<tr>
<td>Mel290</td>
<td></td>
</tr>
<tr>
<td>Mel285</td>
<td></td>
</tr>
<tr>
<td>92.1</td>
<td></td>
</tr>
<tr>
<td>Omm1.3</td>
<td></td>
</tr>
<tr>
<td>Omm1</td>
<td></td>
</tr>
</tbody>
</table>

- C918
- Mel290
- Mel285
- 92.1
- Omm1.3
- Omm1

- WT
- GNAQ
- GNA11

(Bar graph showing pg/ml HGF levels for different cell types and conditions.)
Figure 2

A

<table>
<thead>
<tr>
<th></th>
<th>C918</th>
<th>Mel290</th>
<th>Mel285</th>
<th>92.1</th>
<th>Omm1.3</th>
<th>Omm1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>c-Met</td>
<td>Control</td>
<td>c-Met</td>
<td>Control</td>
<td>c-Met</td>
<td>Control</td>
</tr>
<tr>
<td>siRNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-Met</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>C918</th>
<th>Mel290</th>
<th>Omm1.3</th>
<th>Omm1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>c-Met</td>
<td>ALK</td>
<td>ROS1</td>
<td>c-Met</td>
</tr>
<tr>
<td>siRNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-Met</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROS1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

![Graph showing cell viability](image)

D

![Graph showing number of cells migrated](image)
Figure 3

A

% Cell Viability

C918  Mel290  Mel285  92.1  Omm1.3  Omm1

WT GNAQ GNA11

B

WT

C918  Mel290  Mel285  92.1  Omm1.3  Omm1

nM crizotinib

0  2.5  25  250  0  2.5  25  250  0  2.5  25  250

p-Met

p-Met (Long Exposure)

Total Met

p-ALK

Total ALK

p-Ros1

Total Ros1

Tubulin

C

Control  25 nM crizotinib

C918

Mel290

Mel285

92.1

Omm1.3

Omm1
Figure 4

A. 92.1 Xenograft – Tumor volume

- Vehicle Control, p.o. QD x 5 x 4-5 Weeks
- crizotinib 50mg/kg p.o. QD x 5 x 4-5 Weeks

B. Omm1.3 Xenograft – Tumor Volume

- Vehicle Control, p.o. QD x 5 x 4-5 Weeks
- crizotinib 50mg/kg p.o. QD x 5 x 4-5 Weeks

C. Western Blot Analysis

<table>
<thead>
<tr>
<th>92.1</th>
<th>Omm1.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>50 mg/kg crizotinib</td>
</tr>
<tr>
<td>p-Met</td>
<td>Total Met</td>
</tr>
<tr>
<td>p-AKT</td>
<td>Total AKT</td>
</tr>
<tr>
<td>p-ALK</td>
<td>Total ALK</td>
</tr>
<tr>
<td>PARP</td>
<td>Tubulin</td>
</tr>
</tbody>
</table>